Effectiveness of Co-Amoxiclav in Managing Upper Respiratory Tract Infections: A Multicenter Retrospective Real-World Study
Authors/Creators
- 1. Medical Affairs Department, Alkem Laboratories Ltd., Mumbai
Description
Background: Upper respiratory tract infections (URTIs) are among the most common infectious diseases, affecting the nasal passages, pharynx, and larynx. They present a significant health burden, especially in children and individuals with compromised immune systems, leading to symptoms like cough, sore throat, and congestion. The present study aims to assess the effectiveness and safety profile of Co-amoxiclav in managing upper respiratory tract infections (URTIs) across the adult population of India. Methods: A single-arm, multicenter, retrospective, medical records-based, real-world study was conducted, including all adult patients diagnosed with URTIs presented to the Out-Patient Department (OPD) or admitted to the In-Patient Department (IPD) who have been treated with Co-Amoxiclav Therapy. Data were collected at three intervals: baseline (day 0), first follow-up (day 7±2), and second follow-up (day 14±2). Demographic information, medical history, primary diagnosis, vital signs, and laboratory parameters were documented at baseline and follow-ups. Clinical outcomes, microbiological results, and safety data, such as adverse events, were assessed at each follow-up. The statistical analysis in this study employed a combination of descriptive statistics and frequencies, along with the Chi-square test, to evaluate the efficacy of Co-Amoxiclav. Descriptive statistics summarized the characteristics of the sample, providing means, standard deviations, and frequencies for categorical variables. Results: The study included a total of 9233 participants with a mean age of 46.84±16.3. The most frequently encountered URTI was the undifferentiated URTI, accounting for 48% of the total population. A significant proportion of the participants (72%) were prescribed co-amoxiclav 625 mg twice daily for 5 to 7 days. The study reported statistically significant efficacy (92.82%) of co-amoxiclav (p<0.0001) in the treatment of URTIs. Significant improvements in laboratory parameters with C-reactive protein (CRP) levels (p < 0.001) and white blood cell count decrease were observed (p < 0.001). Adverse events were notably rare in the study population, with only 28 cases (0.35%) reporting any treatment-related events. Conclusion: Co-amoxiclav demonstrated excellent efficacy and safety profile in the treatment of upper respiratory tract infection. Further large studies are required to determine the long-term outcomes of co-amoxiclav in the timely management of URTIs.
Abstract (English)
Background: Upper respiratory tract infections (URTIs) are among the most common infectious diseases, affecting the nasal passages, pharynx, and larynx. They present a significant health burden, especially in children and individuals with compromised immune systems, leading to symptoms like cough, sore throat, and congestion. The present study aims to assess the effectiveness and safety profile of Co-amoxiclav in managing upper respiratory tract infections (URTIs) across the adult population of India. Methods: A single-arm, multicenter, retrospective, medical records-based, real-world study was conducted, including all adult patients diagnosed with URTIs presented to the Out-Patient Department (OPD) or admitted to the In-Patient Department (IPD) who have been treated with Co-Amoxiclav Therapy. Data were collected at three intervals: baseline (day 0), first follow-up (day 7±2), and second follow-up (day 14±2). Demographic information, medical history, primary diagnosis, vital signs, and laboratory parameters were documented at baseline and follow-ups. Clinical outcomes, microbiological results, and safety data, such as adverse events, were assessed at each follow-up. The statistical analysis in this study employed a combination of descriptive statistics and frequencies, along with the Chi-square test, to evaluate the efficacy of Co-Amoxiclav. Descriptive statistics summarized the characteristics of the sample, providing means, standard deviations, and frequencies for categorical variables. Results: The study included a total of 9233 participants with a mean age of 46.84±16.3. The most frequently encountered URTI was the undifferentiated URTI, accounting for 48% of the total population. A significant proportion of the participants (72%) were prescribed co-amoxiclav 625 mg twice daily for 5 to 7 days. The study reported statistically significant efficacy (92.82%) of co-amoxiclav (p<0.0001) in the treatment of URTIs. Significant improvements in laboratory parameters with C-reactive protein (CRP) levels (p < 0.001) and white blood cell count decrease were observed (p < 0.001). Adverse events were notably rare in the study population, with only 28 cases (0.35%) reporting any treatment-related events. Conclusion: Co-amoxiclav demonstrated excellent efficacy and safety profile in the treatment of upper respiratory tract infection. Further large studies are required to determine the long-term outcomes of co-amoxiclav in the timely management of URTIs.
Files
IJPCR,Vol16,Issue11,Article151.pdf
Files
(403.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:f5aa7625d0cdea97bb966a033af0398c
|
403.3 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-10-26
Software
- Repository URL
- http://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue11,Article151.pdf
- Development Status
- Active
References
- 1. Thomas M, Bomar P. Upper Respiratory Tract Infection - StatPearls - NCBI Bookshelf. StatPearls Publ. Published online 2024. 2. Jin X, Ren J, Li R, et al. Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. EClinicalMedicine. 2021; 37:100986. doi:10.1016/j.eclinm. 2021.100986 3. National Family Health Survey (NFHS-5), 2019-21. : International Institute for Population Sciences (IIPS); 2021. 4. Liu L, Chu Y, Oza S, et al. National, regional, and state-level all-cause and cause-specific under-5 mortality in India in 2000–15: a systematic analysis with implications for the Sustainable Development Goals. Lancet Glob Health. 2019; 7(6):e721-e734. doi: 10.1016/S2214- 109X(19)30080-4 5. Wenzel RP, Fowler AA. Acute Bronchitis. N Engl J Med. 2006; 355(20):2125-2130. Doi: 10.1056/NEJMcp061493 6. Calderaro A, Buttrini M, Farina B, Montecchini S, De Conto F, Chezzi C. Respiratory Tract Infections and Laboratory Diagnostic Methods: A Review with A Focus on Syndromic PanelBased Assays. Microorganisms. 2022; 10(9):1856. doi: 10.3390/microorganisms1009 1856 7. Juhn YJ. Risks for infection in patients with asthma (or other atopic conditions): Is asthma more than a chronic airway disease? J Allergy Clin Immunol. 2014; 134(2):247-257.e3. doi:10.1016/j.jaci.2014.04.024 8. Laopaiboon M, Panpanich R, Swa Mya K. Azithromycin for acute lower respiratory tract infections. Cochrane Acute Respiratory Infections Group, ed. Cochrane Database Syst Rev. 2015; 2015(3). doi:10.1002/14651858.CD001 954.pub4 9. White AR. Augmentin(R) (amoxicillin/clavulanate) in the treatment of communityacquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother. 2004; 53(90001):3i-20. doi:10.1093/jac/dkh0 50 10.Castle SS. Beta-Lactamase Inhibitors. In: xPharm: The Comprehensive Pharmacology Reference. Elsevier; 2007:1-3. doi:10.10 16/B978-008055232-3.61062-1 11.Choudhury J, Makkar A, Sharma V, et al. A Real-World Perspective of Co-amoxiclav Prescription Pattern with Probiotics for Pediatric Patients with Respiratory Tract Infections: Results of Quantitative and Qualitative Approach in Indian Outpatient Settings. Cureus. Published online March 16, 2023. doi:10.7759/ cureus.36269 12.Evans J, Hanoodi M, Wittler M. Amoxicillin Clavulanate - StatPearls - NCBI Bookshelf. StatPearls Publ. Published online 2024. 13.Namyslowski G, Misiolek M, Czecior E, et al. Comparison of the Efficacy and Tolerability of Amoxycillin/Clavulanic Acid 875mg b.i.d. with Cefuroxime 500mg b.i.d. in the Treatment of Chronic and Acute Exacerbation of Chronic Sinusitis in Adults. J Chemother. 2002; 14(5):508-517. doi:10.1179/joc.2002.14.5.508 14.Seggev JS, Enrique RR, Brandon ML, Larsen LS, Van Tuyl RA, Rowinski CA. A Combination of Amoxicillin and Clavulanate Every 12 Hours vs Every 8 Hours for Treatment of Acute Bacterial Maxillary Sinusitis. Arch Otolaryngol Neck Surg. 1998; 124(8):921. doi:10.1001/archotol.124.8.921 15.Amini M, Yarmohammadi M, Izadi P. A comparing study of clarithromycin XL with coamoxiclav for treatment of chronic sinusitis; a clinical trial. Published online 2009. 16.Bandak SI, Bolzon LD, Turnak MR, Johns D, Henle SK, Allen BS. Cefaclor AF versus amoxycillin/clavulanate in acute bacterial exacerbations of chronic bronchitis: a randomised multicentre study. Int J Clin Pract. 1999; 53(8):578-583. 17.Legnani D, Lombardo VM, Negretto GG, Beghi G, Caratozzolo O. Comparative clinical and microbiological study of amoxycillinclavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis. J Hosp Infect. 1992; 22:69-74. doi: 10.1016/ S0195-6701(05)80009-X 18.Fogarty CM, Cyganowski M, Palo WA, Hom RC, Craig WA. A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: A multicenter, prospective, randomized, investigator-blinded, parallel-group study. Clin Ther. 2002; 24(11):1854-1870. doi: 10.1016/ S0149-2918(02)80084-4 19.Lode H, Magyar P, Muir JF, Loos U, Kleutgens K. Once-daily oral gatifloxacin vs. three-timesdaily co-amoxiclav in the treatment of patients with community-acquired pneumonia. Clin Microbiol Infect. 2004; 10(6):512-520. doi:10. 1111/j.1469-0691.2004.00875.x 20.Van Der Meer V, Neven AK, Van Den Broek PJ, Assendelft WJJ. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ. 2005;331(7507):26. doi:10.1136/ bmj.38483.47818 3.EB 21.Falk G, Fahey T. C-reactive protein and community-acquired pneumonia in ambulatory care: systematic review of diagnostic accuracy studies. Fam Pract. 2008; 26(1):10-21. doi:10. 1093/fampra/cmn095 22.Yebyo H, Medhanyie AA, Spigt M, Hopstaken R. C-reactive protein point-of-care testing and antibiotic prescribing for acute respiratory tract infections in rural primary health centres of North Ethiopia: a cross-sectional study. Npj Prim Care Respir Med. 2016; 26(1):15076. doi:10.1038/npjpc rm.2015.76 23.Huang H, Li L, Wu M, et al. Antibiotics and antibiotic-associated diarrhea: a real-world disproportionality study of the FDA adverse event reporting system from 2004 to 2022. BMC Pharmacol Toxicol. 2023; 24(1):73. doi:10.1186/s40360-023-00710-w 24.Iravani A, Richard GA. Treatment of urinary tract infections with a combination of amoxicillin and clavulanic acid. Antimicrob Agents Chemother. 1982; 22(4):672-677. doi:10.1128/ AAC.22.4.672 25.Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014; 109(7):950-966; quiz 967. doi: 10.1038/ajg. 2014.131 26.DeLemos AS, Ghabril M, Rockey DC, et al. Amoxicillin-Clavulanate-Induced Liver Injury. Dig Dis Sci. 2016; 61(8):2406-2416. doi: 10.1007/s10620-016-4121-6 27.Thong BYH. Update on the management of antibiotic allergy. Allergy Asthma Immunol Res. 2010; 2(2):77-86. doi:10.4168/aair.2010. 2.2.77 28. Adverse Drug Reactions Advisory Committee (ADRAC), Adverse, Drug Reactions Unit (ADRU). Australian Adverse Drug Reactions Bulletin. ADRAC. 1996; 15(2):1-4.